Physician profile
Brian Hibler
NPI 1790147650
$498,161.16
in general payments reported to CMS, 2019-2025
33 companies · $174K in 2025
The $174K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $353 · 2021: $1,877 · 2022: $20K · 2023: $89K · 2024: $213K · 2025: $174K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $399K · Travel and Lodging: $32K · Consulting Fee: $23K · Food and Beverage: $22K · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $398,612.50 |
| Travel and Lodging | $32,214.93 |
| Consulting Fee | $22,728.32 |
| Food and Beverage | $22,040.43 |
| Education | $279.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467,637.25 | 2021-2025 | |
| Allergan, INC. | $15,974.11 | 2020-2022 | |
| Biofrontera INC. | $2,500.89 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $1,644.10 | 2022-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $989.91 | 2023-2025 | Ycanth |
| Incyte Corporation | $968.63 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $924.07 | 2021-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $887.10 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $877.35 | 2020-2025 | Aklief, Nemluvio, Epsolay |
| Lilly USA, LLC | $792.58 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $724.63 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $632.83 | 2021-2025 | |
| Genzyme Corporation | $438.05 | 2022-2025 | |
| Amgen INC. | $429.89 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $415.95 | 2022-2025 | Adbry, Anzupgo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $302.16 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $284.47 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $270.26 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $193.69 | 2021-2023 | Jublia |
| Ucb, INC. | $184.66 | 2020-2024 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $174.13 | 2021-2025 | |
| Epi Health, LLC | $152.18 | 2022 | |
| Pfizer INC. | $150.21 | 2021-2023 | |
| Almirall LLC | $125.17 | 2023-2024 | Seysara, Klisyri |
| Botanix Sb INC | $103.05 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Organon LLC | $78.90 | 2025 | |
| Fidia Pharma USA INC. | $58.05 | 2024 | |
| Cipher Pharmaceuticals US LLC | $44.18 | 2025 | Spinosad, Natroba |
| Blueprint Medicines Corporation | $41.02 | 2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $36.42 | 2025 | Clear+Brilliant |
| Genentech USA, INC. | $29.61 | 2023 | Xolair |
| Strata Skin Sciences, INC. | $15.67 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hibler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.